AADAT and schizophrenia: Inhibitors of KAT2, which reduce kynurenic acid production, are among the most promising candidates in neuroscience for the treatment of schizophrenia and schizoid disorders, while inhibitors of KMO which increase kynurenic acid levels are likely to be of value in regulating the immune system.